Copyright Reports & Markets. All rights reserved.

Global PSMA-labeled Imaging Ligands Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global PSMA-labeled Imaging Ligands Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Gallium-68（Ga-68）
    • 1.3.3 Fluorine-18（F-18）
  • 1.4 Market Analysis by Dosage
    • 1.4.1 Overview: Global PSMA-labeled Imaging Ligands Consumption Value by Dosage: 2021 Versus 2025 Versus 2032
    • 1.4.2 Ready-to-use Drug
    • 1.4.3 Kit-based Radiolabeling
  • 1.5 Market Analysis by Application
    • 1.5.1 Overview: Global PSMA-labeled Imaging Ligands Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.5.2 Initial Staging
    • 1.5.3 Biochemical Recurrence
    • 1.5.4 Theranostics Selection
    • 1.5.5 Others
  • 1.6 Global PSMA-labeled Imaging Ligands Market Size & Forecast
    • 1.6.1 Global PSMA-labeled Imaging Ligands Consumption Value (2021 & 2025 & 2032)
    • 1.6.2 Global PSMA-labeled Imaging Ligands Sales Quantity (2021-2032)
    • 1.6.3 Global PSMA-labeled Imaging Ligands Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Lantheus Holdings
    • 2.1.1 Lantheus Holdings Details
    • 2.1.2 Lantheus Holdings Major Business
    • 2.1.3 Lantheus Holdings PSMA-labeled Imaging Ligands Product and Services
    • 2.1.4 Lantheus Holdings PSMA-labeled Imaging Ligands Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Lantheus Holdings Recent Developments/Updates
  • 2.2 Novartis
    • 2.2.1 Novartis Details
    • 2.2.2 Novartis Major Business
    • 2.2.3 Novartis PSMA-labeled Imaging Ligands Product and Services
    • 2.2.4 Novartis PSMA-labeled Imaging Ligands Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Novartis Recent Developments/Updates
  • 2.3 Curium
    • 2.3.1 Curium Details
    • 2.3.2 Curium Major Business
    • 2.3.3 Curium PSMA-labeled Imaging Ligands Product and Services
    • 2.3.4 Curium PSMA-labeled Imaging Ligands Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Curium Recent Developments/Updates
  • 2.4 Blue Earth Diagnostics
    • 2.4.1 Blue Earth Diagnostics Details
    • 2.4.2 Blue Earth Diagnostics Major Business
    • 2.4.3 Blue Earth Diagnostics PSMA-labeled Imaging Ligands Product and Services
    • 2.4.4 Blue Earth Diagnostics PSMA-labeled Imaging Ligands Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Blue Earth Diagnostics Recent Developments/Updates
  • 2.5 Bayer
    • 2.5.1 Bayer Details
    • 2.5.2 Bayer Major Business
    • 2.5.3 Bayer PSMA-labeled Imaging Ligands Product and Services
    • 2.5.4 Bayer PSMA-labeled Imaging Ligands Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Bayer Recent Developments/Updates
  • 2.6 Advanced Biochemical Compounds(ABX)
    • 2.6.1 Advanced Biochemical Compounds(ABX) Details
    • 2.6.2 Advanced Biochemical Compounds(ABX) Major Business
    • 2.6.3 Advanced Biochemical Compounds(ABX) PSMA-labeled Imaging Ligands Product and Services
    • 2.6.4 Advanced Biochemical Compounds(ABX) PSMA-labeled Imaging Ligands Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Advanced Biochemical Compounds(ABX) Recent Developments/Updates
  • 2.7 Yantai Dongcheng
    • 2.7.1 Yantai Dongcheng Details
    • 2.7.2 Yantai Dongcheng Major Business
    • 2.7.3 Yantai Dongcheng PSMA-labeled Imaging Ligands Product and Services
    • 2.7.4 Yantai Dongcheng PSMA-labeled Imaging Ligands Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Yantai Dongcheng Recent Developments/Updates
  • 2.8 China Isotope & Radiation
    • 2.8.1 China Isotope & Radiation Details
    • 2.8.2 China Isotope & Radiation Major Business
    • 2.8.3 China Isotope & Radiation PSMA-labeled Imaging Ligands Product and Services
    • 2.8.4 China Isotope & Radiation PSMA-labeled Imaging Ligands Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 China Isotope & Radiation Recent Developments/Updates
  • 2.9 Grand Pharmaceutical
    • 2.9.1 Grand Pharmaceutical Details
    • 2.9.2 Grand Pharmaceutical Major Business
    • 2.9.3 Grand Pharmaceutical PSMA-labeled Imaging Ligands Product and Services
    • 2.9.4 Grand Pharmaceutical PSMA-labeled Imaging Ligands Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Grand Pharmaceutical Recent Developments/Updates
  • 2.10 Telix Pharmaceuticals
    • 2.10.1 Telix Pharmaceuticals Details
    • 2.10.2 Telix Pharmaceuticals Major Business
    • 2.10.3 Telix Pharmaceuticals PSMA-labeled Imaging Ligands Product and Services
    • 2.10.4 Telix Pharmaceuticals PSMA-labeled Imaging Ligands Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Telix Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: PSMA-labeled Imaging Ligands by Manufacturer

  • 3.1 Global PSMA-labeled Imaging Ligands Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global PSMA-labeled Imaging Ligands Revenue by Manufacturer (2021-2026)
  • 3.3 Global PSMA-labeled Imaging Ligands Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of PSMA-labeled Imaging Ligands by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 PSMA-labeled Imaging Ligands Manufacturer Market Share in 2025
    • 3.4.3 Top 6 PSMA-labeled Imaging Ligands Manufacturer Market Share in 2025
  • 3.5 PSMA-labeled Imaging Ligands Market: Overall Company Footprint Analysis
    • 3.5.1 PSMA-labeled Imaging Ligands Market: Region Footprint
    • 3.5.2 PSMA-labeled Imaging Ligands Market: Company Product Type Footprint
    • 3.5.3 PSMA-labeled Imaging Ligands Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global PSMA-labeled Imaging Ligands Market Size by Region
    • 4.1.1 Global PSMA-labeled Imaging Ligands Sales Quantity by Region (2021-2032)
    • 4.1.2 Global PSMA-labeled Imaging Ligands Consumption Value by Region (2021-2032)
    • 4.1.3 Global PSMA-labeled Imaging Ligands Average Price by Region (2021-2032)
  • 4.2 North America PSMA-labeled Imaging Ligands Consumption Value (2021-2032)
  • 4.3 Europe PSMA-labeled Imaging Ligands Consumption Value (2021-2032)
  • 4.4 Asia-Pacific PSMA-labeled Imaging Ligands Consumption Value (2021-2032)
  • 4.5 South America PSMA-labeled Imaging Ligands Consumption Value (2021-2032)
  • 4.6 Middle East & Africa PSMA-labeled Imaging Ligands Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global PSMA-labeled Imaging Ligands Sales Quantity by Type (2021-2032)
  • 5.2 Global PSMA-labeled Imaging Ligands Consumption Value by Type (2021-2032)
  • 5.3 Global PSMA-labeled Imaging Ligands Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global PSMA-labeled Imaging Ligands Sales Quantity by Application (2021-2032)
  • 6.2 Global PSMA-labeled Imaging Ligands Consumption Value by Application (2021-2032)
  • 6.3 Global PSMA-labeled Imaging Ligands Average Price by Application (2021-2032)

7 North America

  • 7.1 North America PSMA-labeled Imaging Ligands Sales Quantity by Type (2021-2032)
  • 7.2 North America PSMA-labeled Imaging Ligands Sales Quantity by Application (2021-2032)
  • 7.3 North America PSMA-labeled Imaging Ligands Market Size by Country
    • 7.3.1 North America PSMA-labeled Imaging Ligands Sales Quantity by Country (2021-2032)
    • 7.3.2 North America PSMA-labeled Imaging Ligands Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe PSMA-labeled Imaging Ligands Sales Quantity by Type (2021-2032)
  • 8.2 Europe PSMA-labeled Imaging Ligands Sales Quantity by Application (2021-2032)
  • 8.3 Europe PSMA-labeled Imaging Ligands Market Size by Country
    • 8.3.1 Europe PSMA-labeled Imaging Ligands Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe PSMA-labeled Imaging Ligands Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific PSMA-labeled Imaging Ligands Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific PSMA-labeled Imaging Ligands Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific PSMA-labeled Imaging Ligands Market Size by Region
    • 9.3.1 Asia-Pacific PSMA-labeled Imaging Ligands Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific PSMA-labeled Imaging Ligands Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America PSMA-labeled Imaging Ligands Sales Quantity by Type (2021-2032)
  • 10.2 South America PSMA-labeled Imaging Ligands Sales Quantity by Application (2021-2032)
  • 10.3 South America PSMA-labeled Imaging Ligands Market Size by Country
    • 10.3.1 South America PSMA-labeled Imaging Ligands Sales Quantity by Country (2021-2032)
    • 10.3.2 South America PSMA-labeled Imaging Ligands Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa PSMA-labeled Imaging Ligands Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa PSMA-labeled Imaging Ligands Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa PSMA-labeled Imaging Ligands Market Size by Country
    • 11.3.1 Middle East & Africa PSMA-labeled Imaging Ligands Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa PSMA-labeled Imaging Ligands Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 PSMA-labeled Imaging Ligands Market Drivers
  • 12.2 PSMA-labeled Imaging Ligands Market Restraints
  • 12.3 PSMA-labeled Imaging Ligands Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of PSMA-labeled Imaging Ligands and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of PSMA-labeled Imaging Ligands
  • 13.3 PSMA-labeled Imaging Ligands Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 PSMA-labeled Imaging Ligands Typical Distributors
  • 14.3 PSMA-labeled Imaging Ligands Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global PSMA-labeled Imaging Ligands market size was valued at US$ 2928 million in 2025 and is forecast to a readjusted size of US$ 12023 million by 2032 with a CAGR of 22.8% during review period.
    Prostate-specific membrane antigen (PSMA)-labeled ligands refer to small-molecule compounds that target PSMA and are conjugated with diagnostic radionuclides (primarily Gallium-68 and Fluorine-18) for PET imaging, enabling lesion detection, staging evaluation, and pre-therapeutic patient selection in prostate cancer; they do not deliver therapeutic radiation doses and are classified as radiodiagnostic agents, typically serving as a prerequisite step for PSMA-RLT. The PSMA-labeled ligand market is transitioning from early commercialization to rapid expansion, with a global effective addressable market (EAM) of approximately $2.846 billion in 2025 (including $1.679 billion in commercialized market and $1.0–1.5 billion in convertible in-house demand), corresponding to an annual scan volume of 1.5–2.0 million and a CAGR of 23.3%. Growth is primarily driven by the expansion of F-18 industrialized distribution networks in the U.S. and increasing demand for patient selection alongside broader PSMA-RLT penetration, while the Chinese market remains in an early-stage expansion phase driven by infrastructure build-out.
    On the supply side, nominal “capacity” is essentially the combination of radiopharmacy network coverage and hospital nuclear medicine processing capabilities, where the Fluorine-18 system offers superior scalability through centralized cyclotron production and distribution networks, while the Gallium-68 system is constrained by generator availability and in-house operational capacity, resulting in a decentralized supply structure. In terms of pricing, F-18 finished radiopharmaceuticals (represented by Pylarify) are priced at approximately $3,000–5,000 per dose, while Ga-68 kit-based usage corresponds to $1,000–3,000 per dose; the industry overall exhibits high gross margins of 70–85% (with higher margins for kits but smaller revenue pools). Downstream applications are highly concentrated in the prostate cancer diagnostic workflow (initial staging → recurrence detection → RLT selection), with demand increasingly shifting toward pre-therapy selection as PSMA-targeted therapies expand. The value chain consists of upstream radionuclide supply (F-18, Ga-68 generators) and ligand synthesis, midstream radiopharmaceutical production and distribution networks (a centralized model led by Lantheus Holdings coexisting with a kit-based model led by Telix Pharmaceuticals), and downstream nuclear medicine departments and imaging centers. The global competitive landscape is characterized by an “F-18 oligopoly + Ga-68 dual-core” structure (industrial distribution dominated by Lantheus Holdings, and kit-based pathways led by Novartis and Telix Pharmaceuticals). The industry is fundamentally in a growth stage where demand has been validated but commercialization penetration remains incomplete, driven by the migration from in-house preparation to industrialized distribution and RLT-driven diagnostic demand, while the key uncertainty lies in logistical delivery radius and nuclear medicine infrastructure constraints on F-18 penetration.
    This report is a detailed and comprehensive analysis for global PSMA-labeled Imaging Ligands market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global PSMA-labeled Imaging Ligands market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global PSMA-labeled Imaging Ligands market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global PSMA-labeled Imaging Ligands market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global PSMA-labeled Imaging Ligands market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for PSMA-labeled Imaging Ligands
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global PSMA-labeled Imaging Ligands market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lantheus Holdings, Novartis, Curium, Blue Earth Diagnostics, Bayer, Advanced Biochemical Compounds(ABX), Yantai Dongcheng, China Isotope & Radiation, Grand Pharmaceutical, Telix Pharmaceuticals, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    PSMA-labeled Imaging Ligands market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Gallium-68（Ga-68）
    Fluorine-18（F-18）
    Market segment by Dosage
    Ready-to-use Drug
    Kit-based Radiolabeling
    Market segment by Application
    Initial Staging
    Biochemical Recurrence
    Theranostics Selection
    Others
    Major players covered
    Lantheus Holdings
    Novartis
    Curium
    Blue Earth Diagnostics
    Bayer
    Advanced Biochemical Compounds(ABX)
    Yantai Dongcheng
    China Isotope & Radiation
    Grand Pharmaceutical
    Telix Pharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe PSMA-labeled Imaging Ligands product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of PSMA-labeled Imaging Ligands, with price, sales quantity, revenue, and global market share of PSMA-labeled Imaging Ligands from 2021 to 2026.
    Chapter 3, the PSMA-labeled Imaging Ligands competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the PSMA-labeled Imaging Ligands breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and PSMA-labeled Imaging Ligands market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of PSMA-labeled Imaging Ligands.
    Chapter 14 and 15, to describe PSMA-labeled Imaging Ligands sales channel, distributors, customers, research findings and conclusion.

    Buy now